Latest Financial Position News

Experience Co Limited reported a 5% increase in sales revenue to $67.2 million for 1H26, with underlying EBITDA steady at $10.5 million despite operational challenges. The company is streamlining its portfolio by selling Wild Bush Luxury and focusing on scalable adventure experiences.

Harris Technology Group Limited reported an 18.9% increase in half-year revenue to $8.3 million, turning a modest profit after a prior loss, while flagging ongoing financial uncertainties linked to upcoming debt repayments.

TPC Consolidated Limited reported a 4.1% revenue increase to $103.6 million and a 62% jump in underlying EBITDA for the half-year ended December 2025, while the proposed acquisition scheme faces regulatory hurdles.

Oliver’s Real Food Limited has reported a statutory net profit after tax of $995,000 for the half-year ended December 2025, marking a $1.82 million turnaround from the previous loss. This improvement comes despite a 6.5% revenue decline, driven by strategic store closures and disciplined cost management.

Global Health Limited reports a modest half-year loss reduction alongside a steady rise in recurring SaaS revenue, signaling progress in its digital healthcare transformation.

Audeara Limited reported a strong half-year revenue increase of 63.76% to $2.95 million, alongside a 57% reduction in net loss. However, the company flagged ongoing uncertainty about its ability to continue as a going concern.

Star Combo Pharma reported a 23% decline in revenue to $11.9 million for the half year ended December 2025, driven by the loss of a major OEM contract and closure of its AustoYou retail business. Despite this, operating profit after tax rose 49% to $413,243, reflecting effective cost management.

Vitura Health Limited reported an 8.3% rise in half-year revenues to $67.87 million, driven by medicinal cannabis sales and telehealth services, yet posted a consolidated loss of $986,341 due to margin pressures and increased costs. Leadership changes and strategic investments mark a pivotal phase for the digital health and medicinal cannabis player.

Carnegie Clean Energy reported a $1.7 million loss for the half-year ending December 2025, while pushing forward with key wave energy projects and securing $2.1 million in fresh capital.

Anatara Lifesciences reports a significantly reduced net loss for H1 FY2026, driven by promising pre-clinical results in its anti-obesity program and a successful $1.2 million capital raise. The company also highlights positive Phase II trial outcomes for its gastrointestinal health product GaRP.

Imugene Limited reports a narrower half-year loss as it advances its promising azer-cel CAR T therapy with strong clinical results and FDA backing, supported by a $25 million capital raise.

Optiscan Imaging reports a sharp 43% drop in revenue and a 43% rise in losses for H1 FY26, driven by restricted research funding in key markets. The company bolsters its balance sheet with a $17.75 million capital raise to advance clinical studies and regulatory approvals.